<code id='3D173DA685'></code><style id='3D173DA685'></style>
    • <acronym id='3D173DA685'></acronym>
      <center id='3D173DA685'><center id='3D173DA685'><tfoot id='3D173DA685'></tfoot></center><abbr id='3D173DA685'><dir id='3D173DA685'><tfoot id='3D173DA685'></tfoot><noframes id='3D173DA685'>

    • <optgroup id='3D173DA685'><strike id='3D173DA685'><sup id='3D173DA685'></sup></strike><code id='3D173DA685'></code></optgroup>
        1. <b id='3D173DA685'><label id='3D173DA685'><select id='3D173DA685'><dt id='3D173DA685'><span id='3D173DA685'></span></dt></select></label></b><u id='3D173DA685'></u>
          <i id='3D173DA685'><strike id='3D173DA685'><tt id='3D173DA685'><pre id='3D173DA685'></pre></tt></strike></i>

          explore

          explore

          author:leisure time    Page View:6948
          First Opinion Podcast featured image

          When Prozac first entered the psychiatry scene in in the late ’80s, the profession was still Freud’s territory. Many considered taking medication to treat depression a failure. But that was all about to change, as early stewards like psychiatrist Peter Kramer refused to shy away from the new drug’s potential. These days, he says that people take for granted all of the progress that’s been made with antidepressant treatment in the past three decades.

          “If you were going to be depressed any time in history and were interested in having an effective treatment, you would want to be alive now. But we’ve lost our wonderment about that,” said Kramer, the author of the groundbreaking 1993 book “Listening to Prozac.”

          advertisement

          This week, Kramer joins me to discuss how the country’s relationship with antidepressants has changed since the publication of his book three decades ago. The conversation is based on his First Opinion, “What antidepressants are saying 30 years after the publication of ‘Listening to Prozac.’”

          Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts. And don’t forget to sign up for the First Opinion newsletter to read each week’s best First Opinion essays.

          focus

          Hepatitis C has a cure — but many Americans still lack access to it
          Hepatitis C has a cure — but many Americans still lack access to it

          AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

          read more
          The health care issue Democrats can’t solve: hospital reform
          The health care issue Democrats can’t solve: hospital reform

          MikeReddyforSTATWASHINGTON—Democratsunilaterallydrovemajorreformstothehealthinsuranceandthepharmaceu

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

          RogelioV.Solis/APWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechne